MeiraGTx Holdings PLCNASDAQ:MGTX
- LAST PRICE6.4000
- TODAY'S CHANGE (%)0.0700 (1.1058%)
- Bid / Lots6.3900/ 3
- Ask / Lots6.4100/ 3
- Open / Previous Close6.2800 / 6.3300
- Day Range
- 52 Week Range
- Volume87,018
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MGTX |
|---|---|---|
| 09:32 ET | 2650 | 6.34 |
| 09:35 ET | 200 | 6.41 |
| 09:39 ET | 300 | 6.365 |
| 09:42 ET | 1480 | 6.31 |
| 09:44 ET | 2000 | 6.3184 |
| 09:48 ET | 500 | 6.32 |
| 09:50 ET | 1200 | 6.38 |
| 09:51 ET | 1106 | 6.38 |
| 09:53 ET | 2154 | 6.365 |
| 09:55 ET | 1099 | 6.39 |
| 09:57 ET | 800 | 6.32 |
| 10:00 ET | 500 | 6.3046 |
| 10:04 ET | 3425 | 6.2315 |
| 10:06 ET | 200 | 6.26 |
| 10:09 ET | 1000 | 6.255 |
| 10:11 ET | 300 | 6.21 |
| 10:13 ET | 385 | 6.23 |
| 10:15 ET | 800 | 6.23 |
| 10:18 ET | 598 | 6.23 |
| 10:20 ET | 500 | 6.2319 |
| 10:22 ET | 100 | 6.23 |
| 10:24 ET | 700 | 6.26 |
| 10:26 ET | 801 | 6.22 |
| 10:27 ET | 155 | 6.2166 |
| 10:29 ET | 200 | 6.22 |
| 10:31 ET | 1550 | 6.26 |
| 10:33 ET | 437 | 6.265 |
| 10:36 ET | 1300 | 6.3099 |
| 10:38 ET | 725 | 6.28 |
| 10:40 ET | 200 | 6.3 |
| 10:42 ET | 600 | 6.27 |
| 10:44 ET | 1200 | 6.29 |
| 10:45 ET | 600 | 6.29 |
| 10:47 ET | 1768 | 6.325 |
| 10:49 ET | 213 | 6.3392 |
| 10:51 ET | 400 | 6.32 |
| 10:54 ET | 669 | 6.33 |
| 10:56 ET | 400 | 6.33 |
| 11:02 ET | 700 | 6.36 |
| 11:03 ET | 5300 | 6.39 |
| 11:05 ET | 792 | 6.37 |
| 11:07 ET | 700 | 6.38 |
| 11:12 ET | 600 | 6.34 |
| 11:14 ET | 941 | 6.335 |
| 11:18 ET | 200 | 6.32 |
| 11:20 ET | 200 | 6.33 |
| 11:21 ET | 500 | 6.34 |
| 11:25 ET | 100 | 6.35 |
| 11:30 ET | 682 | 6.37 |
| 11:32 ET | 265 | 6.37 |
| 11:34 ET | 1752 | 6.38 |
| 11:36 ET | 200 | 6.38 |
| 11:38 ET | 320 | 6.42 |
| 11:39 ET | 814 | 6.405 |
| 11:41 ET | 100 | 6.405 |
| 11:43 ET | 1076 | 6.4 |
| 11:45 ET | 503 | 6.38 |
| 11:48 ET | 100 | 6.39 |
| 11:52 ET | 2800 | 6.4 |
| 11:54 ET | 1000 | 6.41 |
| 11:56 ET | 2136 | 6.3901 |
| 11:57 ET | 300 | 6.41 |
| 12:01 ET | 100 | 6.4 |
| 12:03 ET | 300 | 6.39 |
| 12:06 ET | 900 | 6.37 |
| 12:08 ET | 1500 | 6.38 |
| 12:10 ET | 300 | 6.39 |
| 12:12 ET | 200 | 6.4 |
| 12:14 ET | 1100 | 6.4 |
| 12:15 ET | 2966 | 6.425 |
| 12:17 ET | 3215 | 6.4201 |
| 12:19 ET | 200 | 6.42 |
| 12:21 ET | 1123 | 6.4114 |
| 12:24 ET | 1481 | 6.4 |
Nov 24, 2024
Press Release: Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors, from 7:27PM ET on Sunday Nov 24, 2024 by Dow Jones
7:27PM ET on Sunday Nov 24, 2024 by Dow JonesAscentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors, from 7:27PM ET on Sunday Nov 24, 2024 by Dow Jones
7:27PM ET on Sunday Nov 24, 2024 by Dow Jones
Nov 18, 2024
DJ MeiraGTx Holdings Is Maintained at Buy by Chardan Capital, from 5:16PM ET on Monday Nov 18, 2024 by Dow Jones
5:16PM ET on Monday Nov 18, 2024 by Dow Jones
Nov 14, 2024
DJ MeiraGTx Holdings Is Maintained at Outperform by RBC Capital, from 12:11PM ET on Thursday Nov 14, 2024 by Dow Jones
12:11PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
*DJ MeiraGTx Holdings 3Q Loss/Shr 55c >MGTX, from 8:01AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:01AM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MeiraGTx Holdings PLC | 463.4M | -4.9x | --- |
Taysha Gene Therapies Inc | 506.2M | -45.7x | --- |
Verve Therapeutics Inc | 410.6M | -2.1x | --- |
Allogene Therapeutics Inc | 463.4M | -1.7x | --- |
Cartesian Therapeutics Inc | 479.6M | -0.5x | --- |
ProQR Therapeutics NV | 383.4M | -11.1x | --- |
Company Information
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Contact Information
- Headquarters
- 450 EAST 29TH STREET, 14TH FLOORNEW YORK, NY, United States 10016
- Phone
- 646-860-7985
- Fax
- ---
Executives
- Independent Chairman of the Board
- Keith Harris
- President, Chief Executive Officer, Director
- Alexandria Forbes
- Chief Financial Officer, Chief Operating Officer
- Richard Giroux
- General Counsel, Secretary
- Robert Wollin
- Chief Development Officer
- Stuart Naylor
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $463.4M |
|---|---|
Revenue (TTM) | $13.9M |
Shares Outstanding | 78.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-1.30 |
Book Value | $2.17 |
P/E Ratio | -4.9x |
Price/Sales (TTM) | 33.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,266.97% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
